AZ, Chinese Future Industry Investment Fund create Chinese JV

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Chinese Future Industry Investment Fund (FIIF) formed Dizal Pharmaceutical Co. Ltd. to discover, develop and commercialize new compounds in China. The partners will equally own the JV, which will be located in Shanghai’s Pudong district.

The JV will have exclusive, worldwide development and commercialization rights to two preclinical AZ candidates and Chinese rights to a third preclinical product. The undisclosed programs are in oncology, cardiovascular and metabolic diseases, and respiratory. Dizal will also develop new clinical programs...